Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392170 | 1.00 | CHRNA7 (0.61) | CHRNA7ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL6395366 | 0.91 | CHRNA7 (0.58) | CHRNA7ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL6395358 | 0.91 | CHRNA7 (0.58) | CHRNA7ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL6388686 | 0.86 | CHRNA7 (0.51) | CHRNA7ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL5407984 | 0.82 | MAPK14 (0.72) | ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL6482341 | 0.82 | CHRNA7 (0.63) | CHRNA7MAPK14MAOB | |
| SCHEMBL6481419 | 0.82 | CHRNA7 (0.63) | CHRNA7MAPK14MAOB | |
| SCHEMBL6388950 | 0.81 | ROCK2 (0.57) | CHRNA7ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL6392138 | 0.81 | CHRNA7 (0.67) | CHRNA7 | |
| SCHEMBL6392146 | 0.81 | CHRNA7 (0.67) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849620-B2 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PFIZER INC (US) | 2005-02-01 | — | — | US | claimed |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | claimed |
| US-6849620-B2 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PFIZER INC (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | CYP1B1, ABCB1, NAT1 | CHRNA7 1187/4885ROCK2 4353/4885ROCK1 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.